Stock Analysis
BridgeBio Pharma, Inc. Common StockBBIO
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy29 analystsPrice is 36% of the way from the year's low to its high.
Cash covers 32% of debt · FY 2025.
PMP Verdict
Cheap for a reason — weak fundamentals
Risks
- Profitability0
- Growth25
Cheap for a reason — fundamentals remain weak.
Bull Case
- ✓Revenue CAGR 63.8% — durable top-line growth
What's happening with BBIO
Profile
profitability, valuation, growth, moat, financial health and earnings quality lag behind.
How is each axis scored?
- Valuation25/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-3.4%)0/25
- P/S (18.2x)5/25
- EV/EBIT (n/a)10/25
- Growth25/100 · Weak
- Revenue CAGR (63.8%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (n/a)0/25
- Net margin (-97.0%)0/25
- Operating margin (-69.8%)0/25
- Financial Health28/100 · Weak
- Altman Z (-3.84)3/25
- Current ratio (2.77)25/25
- Interest coverage (-3.8x)0/25
- Net cash / debt (D/A 135%)0/25
- Quality30/100 · Weak
- Piotroski F (2/9)5/25
- Beneish M (-4.29)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 7207.2%)0/25
- Moat25/100 · Weak
- ROIC >12% years (n/a)0/25
- Median gross margin (95.8%)25/25
- FCF-positive years (0/7 yrs)0/25
- Worst-year net margin (worst -6913.9%)0/25
Risk Flags
- ⚠Altman Z -3.8 — distress-zone balance sheet
- ⚠Negative FCF margin (-0.6%) — burning cash
- ⚠SBC 20.6% of revenue — real dilution cost
- ⚠7 loss-making years in recent history
- ⚠Interest coverage -3.8× — thin debt cushion
About BridgeBio Pharma, Inc. Common Stock
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. Show more
The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Headquarters: PALO ALTO, CA · Employees: 839 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
25EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-3.4%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -51.1%–-2.5% · 92nd pct
P/S (TTM)18.19xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 11.2x–1194.1x · 12th pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales22.3xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B RatioNeg. EquityC
Grade C: BuybacksPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROENeg. EquityC
Grade C: BuybacksReturn on Equity. Neg. equity = heavy buybacks
ROA-61.2%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-97.0%D
Grade D: LowNet Income / Revenue
Operating Margin-69.8%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin94.4%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-61.1%D
Grade D: LowFCF / Revenue
True FCF Margin-81.7%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
25ERevenue CAGR63.8%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue20.6%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
28EAltman Z-Score-3.84D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.77xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio1.09xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-3.8xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity—
Debt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.32xC
Grade C: PartialCash covers how much of total debt. >1 = could repay all debt from cash
Quality
30DPiotroski F-Score2/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score-4.29A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability7207.2%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.1%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.63xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Kumar Neil Filed | Kumar Neil | SellOpen market sale | -1279 | |
Kumar Neil Filed | Kumar Neil | SellOpen market sale | -8721 | |
Kumar Neil Filed | Kumar Neil | SellOpen market sale | -100 | |
Kumar Neil Filed | Kumar Neil | SellOpen market sale | -1800 | |
Kumar Neil Filed | Kumar Neil | SellOpen market sale | -8100 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Kumar Neil Filed | Kumar Neil | SellOpen market sale | -1199 | |
Kumar Neil Filed | Kumar Neil | SellOpen market sale | -14602 | |
Kumar Neil Filed | Kumar Neil | SellOpen market sale | -17279 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
25EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)95.8%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/7 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-6913.9%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$3.69
Cash & short-term investments per share (Finnhub)
Book Value / Share$0.47
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$1.85B
Total debt obligations (short + long term)
Cash & Equiv.$587.48M
Cash and short-term investments
Net Debt$1.26B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$-2.09B
Shareholders' equity (book value)
Asset / Liability0.31xD
Grade D: RiskyTotal Assets / Total Liabilities
Market
Market Cap$12.97B
Current Market Capitalization
Beta0.95B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: BridgeBio Pharma, Inc. Common Stock (BBIO)
BBIO is down 1.10% at the last close. BridgeBio Pharma, Inc. Common Stock meets only 2 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of -3.84 is below the 1.81 distress threshold — an elevated financial-risk flag. Beneish M-Score of -4.29 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 64% annually — a strong growth profile.
- Free-cash-flow margin is negative (-61%) — the business currently burns cash.
- Company has negative FCF, making debt repayment from operations difficult.
- Interest coverage of -3.8× leaves little room for earnings shocks.
- BridgeBio Pharma, Inc. Common Stock posted a net loss in 7 of 7 available completed fiscal years (2019–2025).
- At a valuation score of 25/100, BBIO trades at a premium to its historical multiples.
See how BBIO ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all BBIO moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 13 | After-hours | 63.04 | -4.12% | -2.21 |
| Sep 23 | After-hours | 65.70 | -5.09% | -2.24 |
| Sep 22 | Regular | 69.29 | +4.06% | 3.03 |
| Sep 22 | After-hours | 70.50 | +5.89% | 4.08 |
Frequently Asked Questions about BBIO
What is the current BridgeBio Pharma, Inc. Common Stock (BBIO) stock price?
BBIO is trading at $66.39 at the last market close, down 1.10% on the session. PreMarketPrice tracks BBIO pre-market, intraday and after-hours prices.
Is BBIO stock a buy right now?
PreMarketPrice's quantitative model rates BridgeBio Pharma, Inc. Common Stock's financial health at 28/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is BBIO stock overvalued?
BridgeBio Pharma, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 25/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does BridgeBio Pharma, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for BBIO. The Earnings section lists recent reports and updates as dates are announced.
What sector does BridgeBio Pharma, Inc. Common Stock operate in?
BridgeBio Pharma, Inc. Common Stock operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does BridgeBio Pharma, Inc. Common Stock do?
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases.
About BridgeBio Pharma, Inc. Common Stock (BBIO) Stock
BridgeBio Pharma, Inc. Common Stock (BBIO) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, BridgeBio Pharma, Inc. Common Stock is trading at $66.39, down 1.10% on the day with a market capitalization of $13.0 billion. The financial health score for BBIO is 28/100, which indicates poor financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BBIO stock.
BBIO Stock Analysis & Key Metrics
On PreMarketPrice, you can track BridgeBio Pharma, Inc. Common Stock (BBIO) across multiple dimensions:
- Pre-market price & movement: Real-time BBIO stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BBIO with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for BridgeBio Pharma, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 28/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BBIO.
- Sector peers: Compare BBIO against 6 other healthcare stocks on key financial metrics.
Is BBIO a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate BridgeBio Pharma, Inc. Common Stock (BBIO) as an investment. The financial health score of 28/100 suggests poor financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.BridgeBio Pharma, Inc. Common Stock (BBIO) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.